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Statement of Translational Relevance. 
Currently clinicians are unable to clearly distinguish between men with less aggressive as 
compared to more aggressive forms of prostate cancer.  Finding genetic variants that identify men 
with aggressive disease, who have a higher risk for prostate cancer-specific mortality, may help 
clinicians make more informed treatment recommendations.  Recent genome-wide association 
studies have identified a number of single nucleotide polymorphisms (SNPs) associated with 
prostate cancer risk, but it is unclear whether these particular SNPs uniquely identify the subset 
of men at higher risk based on clinical features of disease or further enhance risk in men with a 
family history of prostate cancer.  The work presented here addresses these issues and we hope 
that it will encourage future studies aimed at identifying genetic variants that may distinguish 
high-risk subsets of men suitable for novel therapeutic trials. 
Abstract 
Purpose: Two recent genome-wide association studies have highlighted several SNPs purported 
to be associated with prostate cancer risk.  We investigated the significance of these SNPs in a 
population-based study of Caucasian men, testing the effects of each SNP in relation to family 
history of prostate cancer and clinicopathological features of disease.   
Experimental Design: We genotyped 13 SNPs in 1,308 prostate cancer patients and 1,267 
unaffected controls frequency matched to cases by five-year age groups.  The association of each 
SNP with disease risk and stratified by family history of prostate cancer and clinicopathological 
features of disease was calculated using logistic and polytomous regression. 
Results: These results confirm the importance of multiple previously reported SNPs in relation to 
prostate cancer susceptibility; 11 of the 13 SNPs were significantly associated with risk of 
developing prostate cancer.  However, none of the SNP associations were of comparable 
magnitude to that associated with having a first-degree family history of the disease.  Risk 
estimates associated with SNPs rs4242382 and rs2735839 varied by family history, while risk 
estimates for rs10993994 and rs5945619 varied by Gleason score. 
Conclusions: Our results confirm that several recently identified SNPs are associated with 
prostate cancer risk; however the variant alleles only confer a low to moderate relative risk of 
disease and are generally not associated with more aggressive disease features. 
 
Introduction 
 Recent genome-wide association studies (GWAS) have identified multiple genetic 
variants associated with prostate cancer risk (1-5).  At least four separate regions at 8q24 have 
been identified and replicated in numerous studies of both Caucasian and African American men 
(1, 4-18).  Evidence that prostate cancer loci exist on chromosomes 10q11, 17q12 and 17q24 has 
also been presented and replicated in GWA studies (10q11 (1, 4, 19); 17q12 (1, 3, 4, 20); 17q24 
(1, 3)).  In particular, two recent GWAS (1, 4) have each highlighted seven SNPs associated with 
prostate cancer risk, two of which (one at 10q11.2 and one at 11q13.2) were identified in both 
studies. 
Eeles and colleagues (2008) conducted a two-stage GWAS that initially analyzed 1,854 
cases and 1,894 controls for 541,129 SNPs (1).  In order to increase statistical power, cases and 
controls in the first stage of the study were selected according to specific criteria.  Cases had been 
diagnosed as a result of clinical symptoms rather than by routine PSA screening and were further 
enriched by only including men diagnosed at ≤60 years of age or who had a family history of 
prostate cancer.  Controls were screened for serum PSA level and were only included if they were 
≥50 years of age and had a PSA of <0.5 ng/mL.  In stage two of the study, 11 SNPs were 
evaluated in a population-based series of 3,268 cases and 3,366 controls from the UK and 
Australia.  While no specific selection criteria were assigned to stage two participants, over half 
of the control population had a PSA level of <10 ng/mL.  Stage two analyses provided 
confirmatory evidence for 8q24, 17q12 and 17q24 and identified seven distinct novel genomic 
regions on chromosomes 3p12, 6q25, 7q21, 10q11, 11q13, 19q33 and Xp11.  The result at Xp11 
supports results from a GWAS published concurrently by Gudmundsson et al. (2008) (2). 
Thomas and colleagues (2008) also conducted a two-stage GWAS with 527,869 SNPs in 
1,172 prostate cancer cases and 1,157 controls who volunteered for the Prostate, Lung, Colorectal 
and Ovarian (PLCO) cancer screening trial (4).  In stage one, cases were over-sampled to yield 
688 aggressive cases (Gleason score ≥7 and/or disease stage III-IV) and 484 non-aggressive cases 
(Gleason score <7 and disease stage I-II).  Controls were PSA-screened negative at baseline and 
all participants were of European ancestry.  The second stage involved analyzing the most 
promising 26,958 SNPs (p<0.068) in 3,941 cases and 3,964 controls from four independent 
studies of men of European background from the US, Finland and France.  Seven SNPs achieved 
or approached genome-wide significance (p<10-7) in the combined analysis of the two stages: 
three have been previously reported on chromosomes 8q24 (2 independent SNPs) and 17q12, 
while four represent novel SNPs on chromosomes 7p15, 10q11, 10q26 and 11q13. 
We were invited to participate in replication efforts for the two above-mentioned studies.  
In an effort to confirm the above results and determine the significance of these SNPs in a 
population-based study, we genotyped 13 SNPs in DNA samples from Caucasian men from King 
County, Washington.  The selected SNPs include seven highlighted by Eeles and colleagues 
(2008) and seven highlighted by Thomas and colleagues (2008).  One SNP at 10q11 overlapped 
both studies.  We were particularly interested in testing the effects of each SNP in relation to 
family history of prostate cancer and clinicopathological features of more aggressive disease.  
 
Materials and Methods 
Study Population.  The study population consists of participants from one of two 
population-based, case-control studies of prostate cancer in Caucasian and African American 
residents of King County, Washington (Study I and Study II), whose collection methodologies 
have been previously described in detail (21, 22).  Briefly, Study I cases were diagnosed between 
January 1, 1993, and December 31, 1996 and were 40-64 years of age at diagnosis.  Study II 
cases were diagnosed between January 1, 2002, and December 31, 2005 and were 35-74 years of 
age at diagnosis.  Overall, 2,244 eligible prostate cancer patients were identified, 1,754 (78.2%) 
were interviewed, and blood samples yielding sufficient DNA for genotyping were drawn from 
1,457 (83.1%) cases who completed a study interview.  A comparison group of controls without a 
self-reported physician’s diagnosis of prostate cancer was identified using random digit dialing.  
Controls were frequency matched to cases by five-year age groups and recruited evenly 
throughout each ascertainment period for cases.  A total of 2,448 men were identified who met 
the eligibility criteria, 1,645 (67.2%) were interviewed and of these men blood samples were 
drawn and DNA prepared from 1,352 (82.2%) using standard protocols.  For these analyses, only 
Caucasian participants with DNA were included (1,308 cases and 1,267 controls). 
 Subjects in both studies completed in-person interviews conducted by trained male 
interviewers using standardized questionnaires.  Information was collected on family structure 
and cancer history, medical history, and social and demographic factors.  Clinical information on 
cases, including Gleason score, tumor stage, serum prostate specific antigen (PSA) level at 
diagnosis and primary treatment, was obtained from the SEER cancer registry.  All study 
procedures were approved by the Fred Hutchinson Cancer Research Center institutional review 
board and the National Human Genome Research Institute.  Written informed consent was 
obtained from all study participants prior to participation. 
SNP genotyping.  A total of 13 SNPs were genotyped using the Applied Biosystems 
(ABI) SNPlex™ Genotyping System.  Identification of the specific SNP alleles was carried out 
using the ABI 3730xl DNA Analyzer with GeneMapper® software 
(www.appliedbiosystems.com).  Quality control included genotyping of 144 blind duplicate 
samples distributed across all genotyping batches.  There was 100% agreement between blind 
duplicate samples for all 13 SNPs.  Each batch of DNA aliquots genotyped incorporated similar 
numbers of case and control samples, and laboratory personnel were blinded to the case-control 
status of samples. 
Statistical Analyses.  Departure from Hardy-Weinberg equilibrium was assessed for each 
SNP separately in controls.  Unconditional logistic regression models were used to estimate odds 
ratios (OR) and 95% confidence intervals (95% CI) to measure the association between 
individual SNP genotypes and prostate cancer risk (23).  Differences in risk estimates by first-
degree family history of prostate cancer (yes versus no) were tested by including an interaction 
term in the regression model and comparing the -2 log likelihoods for the full (main effects plus 
the interaction term) and reduced (main effects only) models.  Age at reference date and potential 
confounding factors, including prostate cancer screening history (Never, DRE only, or PSA 
tested within the 5 years prior to reference date) and first-degree family history of prostate 
cancer, were examined to see if such factors changed the risk estimates by ≥10%.  After these 
tests, only age at reference date was included in the final models.  Differences in mean PSA 
levels across SNP genotypes in a sample of controls (n=383) were tested using log-transformed 
PSA in an ANOVA test.  Polytomous regression models were used to generate ORs and 95% CIs 
for the association between SNP genotypes and cases stratified by disease aggressiveness (less 
versus more), Gleason score [≤7 (3+4) versus ≥7 (4+3)], and tumor stage (local versus 
regional/distant) compared to controls.  More aggressive cases were those with either a Gleason 
score of ≥7 (4+3), regional or distant stage disease, or a PSA level ≥20 ng/mL at diagnosis.  A 
chi-square test was used to test for significant differences in risk estimates between lower and 
higher Gleason scores.  Log-additive (trend), recessive and dominant models were considered for 
each SNP and the model with the best fit was chosen for presentation (i.e., the model for which 
the P value was the smallest).  Analyses were performed using SAS version 9.1.3. 
A permutation procedure was used to account for the effect of multiple testing.  Pairs of 
case-control labels and ages were permuted in order to approximate the distribution of the age-
adjusted p-values under the null hypothesis.  Five-year age group and case-control labels were 
permuted together to preserve any relationship that may exist between age and case-control status 
and allow age-adjusted p-values to be calculated for each permutation that are consistent with the 
original analysis.  For each permutation, log-additive, recessive and dominant models were fit for 
all SNPs and the minimum of the p-values kept for each.  The p-values were ordered to 
approximate the null distribution of the order statistics for the p-values, i.e., minimum p-value, 
second smallest p-value, etc.  The original p-values were also ordered and permutation p-values 
were calculated by comparing the ordered p-values to the null distribution for the appropriate 
order statistic.  Permutation p-values can be interpreted as the probability of observing a p-value 
less than or equal to what was observed for the given order statistic under the null hypothesis of 
no association with disease for any of the 13 SNPs.  For example, the minimum p-value was 
compared to the null distribution for the minimum p-value and the corresponding permuted p-
value can be interpreted as the probability of the minimum p-value being less than or equal to the 
observed minimum p-value under the null hypothesis.  The same is true for the second smallest 
p-value, the third smallest p-value, etc.  The permutation approach to approximating the null 
distribution of the order statistics will be valid regardless of any correlation between the SNPs.  A 
SNP was considered to be significantly associated with prostate cancer risk if the nominal p-
value and the permuted p-value were both less than 0.05. 
 
Results 
Genotype distributions of all SNPs were consistent with Hardy-Weinberg equilibrium in 
the control population.  There were no significant differences in the allele frequencies of 
rs5945619 on the X chromosome in our population compared to those in the control population 
of Eeles and colleagues (2008) and the HapMap Centre d’Etude du Polymorphisme Humain 
(CEPH) population (www.hapmap.org).  Of the 13 SNPs investigated, 11 were significantly 
associated with prostate cancer risk in our population (Table 1), with rs10993994 on 10q11 and 
rs4430796 on 17q12 showing the strongest associations (OR=1.31; 95% CI 1.17-1.47; OR=0.77; 
95% CI 0.69-0.86, respectively).  All SNPs that were significantly associated with prostate 
cancer remained significant after adjusting for multiple comparisons. 
A first-degree family history of prostate cancer is associated with a 2- to 3-fold increase in 
risk for disease (24, 25), and has been used to identify men who may have an inherited 
predisposition.  In the case-control population studied here, an OR of 2.19 (95% CI 1.77-2.74; 
p<0.0001) was observed for prostate cancer in Caucasian men with a first-degree family history 
of disease.  None of the SNPs tested were associated with risk estimates for prostate cancer that 
were of comparable magnitude to that associated with having a family history of disease.  Nor, 
for the majority of SNPs tested, was risk modified according to the presence or absence of a 
family history of prostate cancer (Table 2).  Stratifying by family history did, however, reveal 
altered risk estimates associated with SNPs rs2735839 and rs4242382.  The minor allele of 
rs2735839, located on chromosome 19q33.3, is associated with a decreased risk of prostate 
cancer in men without a family history of disease (OR=0.76; 95% CI 0.64-0.91).  However in 
men with a family history, there is no association (OR=1.40; 95% CI 0.91-2.20; interaction 
p=0.01).  Because of it’s proximity to the gene encoding PSA, we also examined the relationship 
between SNP rs2735839 and PSA levels in a sample of 383 controls.  We found a statistically 
significant association between mean PSA level and rs2735839 genotype (GG = 1.44; GA = 1.20; 
AA = 0.78; p=0.0085).  The minor allele of rs4242382, located in region 1 of the risk locus on 
8q24, is associated with an increase in risk of prostate cancer in men without a family history 
(OR=1.53; 95% CI 1.27-1.85), but in those men with a family history of the disease, there is no 
association with risk (OR=0.80; 95%CI 0.54-1.21; interaction p=0.004).  However, after 
accounting for the effects of multiple testing, neither of the above interactions retained significant 
p-values.  To investigate these two SNPs further, we generated risk estimates of prostate cancer 
in men carrying the minor risk allele of the SNP in addition to having a family history of disease.  
For carriers of the rs2735839 risk allele (AA + family history vs. GG + no family history) there 
was an OR of 3.87 (95% CI 1.71-8.35), which is greater than the risk associated with having a 
family history alone.  By comparison, for carriers of the rs4242382 risk allele (AA + family 
history vs. GG + no family history) there was an OR of 1.69 (95% CI 0.82-3.47), which was 
similar to the risk associated with having a family history alone. 
A major goal of current research is to discover markers that may predict men in whom 
prostate cancer will recur, progress and lead to cancer-specific death.  We examined whether any 
of the SNPs recently discovered by the two GWA studies (1, 4) were associated with Gleason 
score, tumor stage, or a composite variable indicating more aggressive disease.  The ORs for 
prostate cancer did not differ significantly by disease aggressiveness or stage (data not shown).  
However, the association of two SNPs with prostate cancer risk did vary by Gleason score (Table 
3).  The minor allele of rs10993994 at 10q11.23 was associated with an increased risk of prostate 
cancer in cases with a lower Gleason score [≤7 (3+4); OR=1.36; 95% CI 1.21-1.54].  However, 
in those cases with a higher Gleason score [≥7 (4+3)] there was no association (OR=1.04; 95% 
CI 0.84-1.30; interaction p=0.02).  The minor allele of rs5945619 at Xp11.22 was more strongly 
associated with risk of prostate cancer in cases with higher (OR=1.33; 95% CI 1.14-1.55) than 
lower Gleason scores (OR=1.12; 95% CI 1.02-1.22; interaction p=0.03).  After accounting for the 
effects of multiple testing, neither of the above interaction p-values was significant. 
 
Discussion 
In the analyses presented here, we examined the association between prostate cancer risk 
and 13 SNPs recently highlighted by two GWAS (1, 4).  Overall, SNPs on chromosomes 6q25, 
7p15, 7q21, 8q24, 10q11, 11q13, 17q12, 19q33 and Xp11 were significantly associated with 
prostate cancer risk in our population-based study. 
Of the seven SNPs described by Eeles et al. (2008), only one, rs2660753 at 3q12, was not 
significantly associated with prostate cancer risk in our population.  This result is consistent with 
a recent replication study presented by Kote-Jarai and colleagues (2008) that examined data from 
the PRACTICAL (Prostate cancer association group to investigate cancer associated alterations 
in the genome) consortium and includes studies from 13 centers (19).  They observed a weaker 
association of SNP rs2660753 with prostate cancer risk than previously reported (1).  In stage 
two of the initial study by Eeles et al. (2008) a per allele OR of 1.18 (95% CI: 1.06-1.31) was 
observed (1), while a reduced OR of 1.08 (95% CI: 1.00-1.16) was noted in the PRACTICAL 
replication study (19).  This latter result could be driven in part by the study population presented 
here, which is a part of PRACTICAL and provided the largest number of cases and controls to 
that consortium effort (19).  Of the seven putatively risk-associated SNPs reported by Thomas 
and colleagues (2008) (4), again only one, rs4962416, was not significantly associated with 
prostate cancer risk in our study.  A number of explanations could account for the lack of an 
association between these SNPs, rs2660753 and rs4962416, in our study.  It may be due to 
different study designs and populations, the reduced sample size of our study compared to the 
initial GWAS or, alternatively, these differences may be due to chance.  Additional studies are 
needed to determine the significance of the relationship between rs2660753 and rs4962416 and 
prostate cancer risk. 
We then considered whether a first-degree family history of prostate cancer modified the 
effect of each SNP investigated.  Stratification according to family history did not significantly 
modify the effect of most SNPs, except two.  SNP rs2735839 at 19q33.3 is situated amongst a 
cluster of kallikrein genes, including KLK3 that encodes prostate-specific antigen (PSA) (26).  
The minor allele is associated with a significantly reduced risk of prostate cancer in men without 
a family history, while no association was seen in men with a family history of disease.  
However, this result could be due to chance, given the limited number of cases and controls with 
a family history.  There is currently debate as to whether the association previously reported 
between this polymorphism and prostate cancer risk is confounded by PSA screening.  The 
association with rs2735839 was first observed in a GWAS where controls had a baseline PSA of 
<0.5ng/mL (1).  In the concurrent CGEMS GWAS, an association between this SNP and prostate 
cancer risk was not identified (4), and when rs2735839 was examined among controls only, a 
strong correlation was found with PSA levels (27).  In our study we found a significant 
association between prostate cancer risk and rs2735839 and we also found a significant 
association between PSA level and rs2735839 genotype (p=0.0085), where the minor allele was 
associated with a decrease in mean PSA levels in controls.  As PSA screening was prevalent in 
men in our study (73% of men with a family history and 58% of men without a family history 
reported having a PSA test within the past five years), it may be that the decrease in risk 
associated with rs2735839 is due to confounding.  Adjusting for prostate cancer screening history 
did not significantly change our risk estimate, but the adjusted confidence interval includes the 
null.  In addition, the association between rs2735839 and prostate cancer risk has been replicated 
in other populations where PSA screening is virtually absent (19).  It is clear that the relationship 
between this SNP and prostate cancer risk needs to be investigated in additional datasets before 
we can determine whether there is a true association with risk of disease. 
The effect of rs4242382 at 8q24 was also modified by family history.  The minor allele 
was associated with a significant increase in risk in men without a family history of prostate 
cancer but not in those with a family history of the disease.  This result appears to reflect the 
somewhat higher MAF in controls with a family history than in controls without a family history 
of prostate cancer.  As the control group is population-based and family history wasn’t a 
determining factor for inclusion, this may reflect a true difference in the effect of this SNP on 
prostate cancer risk according to family history of the disease.  However, the result may also be 
due to the limited number of cases and controls with a family history of prostate cancer in this 
population.  The results from this analysis are in contrast to a previous study by Wang and 
colleagues (2007) (17).  That study examined SNP rs1447295, which is in complete linkage 
disequilibrium (r2=1) with rs4242382, and found a stronger association between rs1447295 SNP 
genotype and risk in familial prostate cancer cases compared to controls than that observed 
between sporadic prostate cancer cases versus controls.  It has to be noted that for both of the 
associations described above, the analyses are underpowered due to the limited number of cases 
and controls with a family history of prostate cancer. 
Currently clinicians are unable to distinguish between those patients with more aggressive 
forms of prostate cancer that may lead to adverse outcomes and those whose disease will follow a 
more indolent course.  There is a need for markers that can identify men who may benefit most 
from aggressive treatment regimens or early phase clinical trials.  deCODE genetics currently 
offers an eight marker deCODE ProCaTM genetic risk profile for Caucasian males of European 
ancestry, however it is not a determinative diagnostic test nor do the SNP genotypes correlate 
with more aggressive prostate cancer features (www.decodediagnostics.com).  Zheng and 
colleagues (2008) have also proposed a five SNP genetic test panel that purports to identify men 
with an increased risk of disease (28).  The relative risk estimate is 4.47 (95% CI 2.93-6.80) for 
the small proportion of men having four of the five at-risk alleles.  However, this test provides no 
greater predictive value than having a strong family history defined by having two or more 
affected first degree relatives (OR 4.9: 95% CI 2.0-12.3 (29); OR 5.08: 95% CI 3.31-7.79 (25)).  
In addition, a recent analysis (30) has shown that these five SNPs do not improve prediction 
models for risk of developing prostate cancer or of disease-specific mortality in Caucasian men 
once currently known risk predictors (age, serum PSA and family history) and outcome 
predictors (age, diagnostic PSA, Gleason score, stage, primary treatment), respectively, are taken 
into account. 
None of the SNPs examined in our case-control study were associated with a composite 
measure of disease aggressiveness or tumor stage.  However, the effects of rs10993994 and 
rs5945619 on prostate cancer risk were significantly different by Gleason score.  SNP 
rs10993994, at 10q11, was associated with a significantly increased risk of disease in men with 
lower Gleason scores but not in men with higher Gleason scores.  This SNP lies two base pairs 
upstream of the transcription start site of MSMB, a gene encoding prostatic secretory protein of 
94 amino acids (PSP94), which is secreted into both seminal fluid and blood (31-33).  PSP94 is a 
tumor suppressor protein that may impede prostate cancer growth through the promotion of 
apoptosis (32), inhibition of the secretion of a matrix metalloproteinase that is implicated in 
tumor metastasis (31), and by decreasing tumor-associated, VEGF-mediated vascularization (34).  
Given the function of this protein, it is not clear why there is an association limited to cases with 
a lower rather than a higher Gleason score; this result may be due to the smaller number of cases 
in the higher Gleason score group or another gene(s) in this region, and not MSMB, may be 
contributing to the deleterious effect. 
The effect of rs5945619 at Xp11 on prostate cancer risk was also modified by Gleason 
score, as there was a significant increase in risk of disease in cases with a higher compared to 
lower Gleason score (interaction p=0.03).  SNP rs5945619 lies in a two Mb LD block between 
the NUDT10 and NUDT11 genes.  While little is known about these particular genes, they belong 
to a subgroup of proteins that have been functionally linked to vesicle trafficking, stress 
responses, DNA repair, and apoptosis (35).  Although the test for homogeneity between cases 
with lower versus higher Gleason scores is only nominally significant, the potential role that 
these genes play in tumor development, and the direction of the association, suggests that this 
finding warrants replication in a larger data set.  While not statistically significant, the relative 
risk of prostate cancer was also greater in men with a higher Gleason score than in those with 
comparatively lower scores in the replication study of Kote-Jarai and colleagues (2008) (19). 
The results presented here confirm the importance of a number of recently highlighted 
loci in prostate cancer susceptibility, even though the variant alleles of these SNPs only confer a 
low to moderate association with risk of the disease.  The effects of most of these polymorphisms 
do not appear to be modified by a family history of prostate cancer, except for rs4242382 at 8q24 
and rs2735839 at 19q33.  Two SNPs, rs10993994 at 10q11 and rs5945619 at Xp11, were 
associated with Gleason score, while the remaining SNPs were not associated with indicators of 
disease aggressiveness or tumor stage.  One shortcoming of this study was the limited power due 
to the smaller numbers in the stratified sub-groups.  Because of this, it is important that these 
results be replicated in larger population-based studies.  In conclusion, while there has recently 
been success in identifying prostate cancer susceptibility loci, future studies should also focus on 
identifying genetic variants that predict risk of more aggressive disease and thereby may predict 
which patients are at higher risk for subsequent metastasis and disease-specific mortality. 
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Table 1. Association results for 13 susceptibility SNPs and prostate cancer risk in Caucasians, King County, WA  
    MAF    
SNP Alleles‡ Chromosome Model Cases (n=1308) Controls (n=1267) OR§ 95% CI p-value 
rs2660753* C/T 3p12.1 Trend 0.12 0.11 1.09 0.92 - 1.30 0.33 
rs9364554* C/T 6q25.3 Dominant 0.33 0.29 1.39 1.18 - 1.62 4.4x10-5 
rs10486567† G/A 7p15.2 Trend 0.20 0.24 0.80 0.69 - 0.91 8.9x10-4 
rs6465657* T/C 7q21.3 Trend 0.49 0.45 1.16 1.04 - 1.30 7.9x10-3 
rs6983267† G/T 8q24.21 Trend 0.45 0.50 0.83 0.74 - 0.93 1.0x10-3 
rs4242382† G/A 8q24.21 Trend 0.14 0.10 1.39 1.18 - 1.66 1.3x10-4 
rs10993994*,† C/T 10q11.23 Trend 0.44 0.38 1.31 1.17 - 1.47 3.7x10-6 
rs4962416† T/C 10q26.13 Trend 0.28 0.27 1.06 0.94 - 1.20 0.35 
rs7931342* G/T 11q13.2 Trend 0.45 0.50 0.82 0.73 - 0.91 4.8x10-4 
rs10896449† G/A 11q13.2 Dominant 0.45 0.50 0.70 0.58 - 0.83 8.3x10-5 
rs4430796† A/G 17q12 Trend 0.43 0.50 0.77 0.69 - 0.86 3.2x10-6 
rs2735839* G/A 19q33.3 Trend 0.13 0.15 0.84 0.72 - 0.99 0.04 
rs5945619* T/C Xp11.22 Trend 0.40 0.33 1.15 1.06 - 1.24 1.1x10-3 
*Eeles et al (2008); †Thomas et al (2008); ‡Major/minor alleles, based on frequencies in controls; §Adjusted for age. 
 
Table 2. Association between 13 SNPs and risk of prostate cancer stratified by family history in Caucasians, King County, WA 
   No Family History Family History  
   MAF*   MAF    
SNP Chromosome Model Cases n=1025 
Controls 




n=142 OR 95% CI p-value
† 
rs2660753 3p12.1 Trend 0.12 0.11 1.09 0.90 - 1.32 0.13 0.12 1.04 0.67 - 1.60 0.84 
rs9364554 6q25.3 Dominant 0.33 0.29 1.38 1.16 - 1.64 0.35 0.29 1.38 0.91 - 2.09 0.94 
rs10486567 7p15.2 Trend 0.2 0.24 0.80 0.69 - 0.93 0.19 0.23 0.79 0.56 - 1.12 0.95 
rs6465657 7q21.3 Trend 0.49 0.45 1.17 1.03 - 1.32 0.49 0.45 1.15 0.86 - 1.54 0.94 
rs6983267 8q24.21 Trend 0.45 0.50 0.83 0.73 – 0.94 0.44 0.49 0.84 0.63 - 1.11 0.97 
rs4242382 8q24.21 Trend 0.14 0.10 1.53 1.26 - 1.85 0.13 0.16 0.80 0.53 - 1.19 0.004 
rs10993994 10q11.23 Trend 0.44 0.38 1.30 1.15 - 1.47 0.44 0.36 1.42 1.04 - 1.92 0.60 
rs4962416 10q26.13 Trend 0.28 0.27 1.06 0.93 - 1.21 0.28 0.26 1.12 0.81 - 1.54 0.76 
rs7931342 11q13.2 Trend 0.45 0.49 0.85 0.75 - 0.97 0.42 0.51 0.67 0.49 - 0.90 0.14 
rs10896449 11q13.2 Dominant 0.46 0.50 0.75 0.62 - 0.92 0.42 0.52 0.49 0.29 - 0.79 0.09 
rs4430796 17q12 Trend 0.43 0.49 0.78 0.69 - 0.88 0.43 0.53 0.68 0.51 - 0.92 0.43 
rs2735839 19q33.3 Trend 0.12 0.16 0.76 0.64 - 0.91 0.16 0.12 1.41 0.91 - 2.17 0.01 
rs5945619 Xp11.22 Trend 0.4 0.32 1.18 1.08 - 1.29 0.38 0.39 0.97 0.79 - 1.20 0.10 
*Minor Allele Frequency; †Comparison of risk estimates for SNP genotypes in the presence and absence of family history









Cases - Lower Gleason Scores‡ 
(n=1102) 
Cases - Higher Gleason 
Scores§ (n=202)  
SNP Chromosome Model* MAF† MAF OR 95% CI MAF OR 95% CI p-value|| 
rs2660753  3p12.1 Trend 0.11 0.12 1.07 0.89 - 1.28 0.13 1.19 0.86 - 1.64 0.53 
rs9364554  6q25.3 Dominant 0.29 0.34 1.43 1.21 - 1.68 0.31 1.18 0.87 - 1.60 0.24 
rs10486567  7p15.2 Trend 0.24 0.2 0.79 0.69 - 0.91 0.21 0.81 0.62 - 1.06 0.86 
rs6465657 7q21.3 Trend 0.45 0.49 1.20 1.07 - 1.35 0.45 0.98 0.79 - 1.22 0.08 
rs6983267 8q24.21 Trend 0.50 0.45 0.82 0.73 - 0.92 0.47 0.90 0.72 - 1.12 0.38 
rs4242382  8q24.21 Trend 0.1 0.14 1.37 1.15 - 1.64 0.15 1.53 1.13 - 2.08 0.47 
rs10993994  10q11.23 Trend 0.38 0.45 1.36 1.21 - 1.54 0.39 1.04 0.84 - 1.30 0.02 
rs4962416  10q26.13 Trend 0.27 0.28 1.06 0.94 - 1.21 0.28 1.04 0.82 - 1.31 0.83 
rs7931342  11q13.2 Trend 0.5 0.44 0.81 0.72 - 0.91 0.46 0.85 0.68 - 1.06 0.65 
rs10896449  11q13.2 Dominant 0.5 0.45 0.70 0.58 - 0.84 0.46 0.69 0.49 - 0.96 0.94 
rs4430796  17q12 Trend 0.5 0.43 0.76 0.68 - 0.86 0.44 0.79 0.63 - 0.98 0.78 
rs2735839  19q33.3 Trend 0.15 0.13 0.86 0.73 - 1.02 0.12 0.74 0.53 - 1.02 0.34 
rs5945619  Xp11.22 Trend 0.33 0.39 1.12 1.02 - 1.22 0.47 1.33 1.14 - 1.55 0.03 
*Model of best fit; † Minor allele frequency; ‡Gleason score ≤7 (3+4); §Gleason score ≥7 (4+3); ||Test for homogeneity of ORs across Gleason score groups. 
 
